22
Views
0
CrossRef citations to date
0
Altmetric
Review

Therapeutic vaccines

Pages 353-364 | Published online: 24 Feb 2005

Bibliography

  • Cohen S, Shafferman A (Eds.), Plenum Press, New York (1996):183–189.
  • BLAMEY RW: The introduction of the LHRH agonist, goserelin (7oladex') into clinical practice for endocrine-related cancer. JOURNAL (1997) 4:229–232.
  • APHTON CORPORATION, INC.: Corporate Statements. http://www.aphton.com
  • GLOVER JF, EN WRIGHT WJ, RUSHTON A: A GnRH analogue based immunotherapeutic for the palliative therapy of prostate cancer: pharmacological studies in the rat. British Prostate Group Meeting. York, UK (March 1996) :31. Abstract.
  • PROTEUS INTERNATIONAL PLC: Annual Report and Accounts (1997). http://www.proteus.co.uk.
  • New antiplatelet drugs. Drugs & Market Development (1997) 8(3):56–57.
  • HERSEY P: Melanoma vaccines: prospects for the treatment of melanoma. Exp. Opin. Invest. Drugs (1997) 6(3):267–277.
  • SPITLER LE, HARRIS DT, MASTRANGELO MJ, et al.: Clinical trials of cancer vaccines. Proceedings of the 3rd International Conference on Engineered Vaccines for Cancer and AIDS. Cambridge Symposia (1996).
  • APHTON CORPORATION, INC.: Corporate Statements. http://www.aphton.com
  • PROTEUS INTERNATIONAL PLC: Press Release (5 March 1998). http://www.proteus.co.uk.
  • NEEFJES JJ, MOMBURG F: Cell biology of antigen presentation. Curr. Opin. Immunol. (1993) 5:27–34.
  • ENGELHARD VH: How cells process antigens. Sci. Am. (August 1994):44–51.
  • GREGORIADIS G: Immunological adjuvants: a role for liposomes. Immunology Today (1990) 11(3):89–97.
  • BREWER JM, ALEXANDER J: Studies on the adjuvant activity of non-ionic surfactant vesicles: adjuvant-driven IgG2a production independent of MHC control. Vaccine (1994) 12(7):613–619.
  • GUPTA RK, RELYVELD EH, LINDBLAD EB, et al.: Adjuvants - a balance between toxicity and adjuvanticity. Vaccine (1993) 11 (3) :293–305.
  • BOON T: Teaching the immune system to fight cancer. Sci. Am. (March 1993):32–39.
  • DONNELLY JJ, ULMER JB, LIU MA: Immunisation with polynucleotides: a novel approach to vaccination. The Immunologist (1994) 2(1) :20–26.
  • POWDERJECT PHARMACEUTICALS PLC: Powderject & GlaxoWellcome sign DNA vaccine agreement. Press Release (5 March 1998).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.